P seudomonas aeruginosa is a ubiquitous aerobic Gramnegative organism that rarely causes disease in healthy individuals. However, P. aeruginosa is a common cause of infection in hospitalized patients, accounting for 11%-14% of all nosocomial infections (1) (2) (3) , including pneumonias, urinary tract infections, and postoperative wound infections. P. aeruginosa ranks third after Escherichia coli and Klebsiella species among Gram-negative bacteria isolated during nosocomial bloodstream infections and seventh among all pathogens (1) . Despite improvements in hospital care, the prognosis of P. aeruginosa bacteremia remains poor, with a crude mortality ranging between 33% and 61% (4, 5) .
The identification of prognostic factors, potentially influencing the mortality of P. aeruginosa bacteremia, is essential to decide whether a subgroup of patients might deserve a particularly aggressive therapeutic approach. Evidence derived from clinical investigations indicates that septic shock, initial site of infection, and immunosuppression at the time of P. aeruginosa bacteremia are considered risk factors for mortality (6) (7) (8) . A key determinant of P. aeruginosa pathogenicity is its ability to deliver a number of toxins into host cells via a type 3 secretion system (TTSS) (9) . The system uses a complex secretion and translocation machinery to inject a set of exotoxins directly into the cytoplasm of eukaryotic cells. Four effector proteins have been identified: ExoU, a phospholipase; ExoY, an adenylate cyclase; and ExoT and ExoS, which are bifunctional proteins (10, 11) . Although all strains harbor type 3 protein secretory genes, only few of these are capable of secreting effector proteins (12) . The expression of the TTSS in P. aeruginosa isolates has been associated with higher bacterial burden and increased mortality in patients with lower respiratory tract infections (13, 14) . To date, no study to our knowledge has investigated the impact of type 3 phenotypic expression on clinical outcomes of P. aeruginosa bloodstream infection. We hypothesized that the production of type 3 secretory proteins is associated with poor outcomes in P. aeruginosa bacteremia.
MATERIALS AND METHODS

Study Population
The study was conducted at the Veterans Affairs Western New York Healthcare System, a tertiary care facility affiliated with the State University of New York at Buffalo following approval by the Institutional Review Board. A retrospective cohort study was established based on P. aeruginosa blood isolates that were stored in a databank from a citywide surveillance initiative implemented in 2004. All corresponding adult patients admitted to the study hospital between January 2004 and June 2010 were identified from the Computerized Background: Pseudomonas aeruginosa bacteremia is a serious and life-threatening infection associated with high mortality. Among the multitude of virulence determinants possessed by P. aeruginosa, the type 3 secretion system has been implicated with more acute and invasive infection in respiratory diseases. However, the relationship between the type 3 secretion system and clinical outcomes in P. aeruginosa bacteremia has not been investigated.
Objectives: To determine the association between the type 3 secretion system virulence factor in P. aeruginosa bloodstream infection and 30-day mortality.
Design: Retrospective analysis of 85 cases of P. aeruginosa bacteremia.
Setting: Tertiary care hospital.
Interventions: Bacterial isolates were assayed in vitro for secretion of type 3 exotoxins (ExoU, ExoT, and ExoS). Strain relatedness was analyzed using randomly amplified polymorphic dNA polymerase chain reaction genotyping. Antimicrobial susceptibilities were determined by means of the Kirby-Bauer disk-diffusion test.
Measurements and Main Results:
At least one of the type 3 secretion system proteins was detected in 37 out of the 85 isolates (44%). Septic shock was identified in 43% of bacteremic patients with type 3 secretion system isolates compared to 23% of patients with type 3 secretion system-isolates (p  .12). A high frequency of resistance in the type 3 secretion system isolates was observed to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%). There was a significant difference in the 30-day cumulative probability of death after bacteremia between secretors and nonsecretors (p  .02). None of the type 3 secretion system patients who survived the first 30 days had a P. aeruginosa isolate which exhibited ExoU phenotype.
Conclusions: The expression of type 3 secretion system exotoxins in bacteremic isolates of P. aeruginosa confers poor clinical outcomes independent of antibiotic susceptibility profile. (Crit Care Med 2012; 40:1157-1163)
Key Words: antimicrobial resistance; bloodstream infection; mortality; Pseudomonas; shock; type III secretion system Patient Record System. Patients with polymicrobial bloodstream infection defined as the isolation of two or more different organisms from the same blood culture were excluded. Patients were included only once in the database to ensure independence of observation. Among those with multiple bacteremic episodes, only the first event was analyzed.
The cohort database included information on sociodemographic characteristics (age, gender, race, and residence), comorbidities, prior antibiotic therapy, severity of illness, source of bacteremia according to the Centers for Disease Control and Prevention criteria (15) , choice and dose of antibiotics used, time to first dose of antimicrobial therapy, and use of corticosteroids and other immunosuppressive agents.
Bacterial Isolates
P. aeruginosa clinical specimens, including the reference strains PA01 and PA103, were streaked onto trypticase soy agar plates and grown in a deferrated dialysate of trypticase soy broth, supplemented with 10 mM nitrilotriacetic acid (Sigma Chemicals), 1% glycerol, and 100 mM monosodium glutamate at 37°C for 17 hrs in a shaking incubator at 250 rpm. Bacteria were removed by centrifugation at 8500 3 g for 5 mins, after which the supernatant was collected and concentrated 20-fold by the addition of a saturated solution of ammonium sulfate.
Immunoblot Analysis
Standardized protein concentrations for the cell-free supernatant were loaded onto 12.5% Tris polyacrylamide gels (Biorad; Hercules, CA) and run under denaturing conditions. Polyacrylamide gels were transferred to polyvinylidene fluoride membrane and immunoblotted with polyclonal rabbit antiserum against ExoU, ExoT, and ExoS, as previously described (16) .
Polymerase Chain Reaction Genotyping
The clonality of P. aeruginosa isolates was determined using randomly amplified polymorphic DNA (RAPD) polymerase chain reaction genotyping as previously described (16) .
Susceptibility Profile
Antimicrobial susceptibilities of P. aeruginosa isolates were determined by means of the Kirby-Bauer disk-diffusion test on Mueller-Hinton agar (BBL Microbiological System, Cockeysville, MD) for imipenem, piperacillintazobactam, cefepime, gentamicin, amikacin, and ciprofloxacin. Minimum inhibitory concentration breakpoints and quality-control protocols were used according to standards established by the Clinical and Laboratory Standards Institute (17) . Isolates with intermediate susceptibility were classified as resistant for analysis.
Definitions
Isolates that secreted type 3 proteins (ExoU, ExoS, ExoT) were referred to as type 3 secretion-positive (TTSS1) isolates, and isolates that did not secrete these proteins were referred to as type 3 secretion-negative (TTSS-). P. aeruginosa bacteremia met the Centers for Disease Control and Prevention criteria for infection (15) . Shock was defined as a decrease in systolic blood pressure to a level of ,90 mm Hg or a decrease of at least 40 mm Hg below baseline blood pressure, despite adequate fluid resuscitation, in conjunction with organ dysfunction and perfusion abnormalities (18) . Severity of illness was determined in accordance with the Acute Physiologic and Chronic Health Evaluation II (19) . The burden of comorbidities was assessed by the Charlson Index (20) .
All patients with septic shock were treated according to a standardized protocol that combined early goal-directed therapy, prompt initiation and appropriate dosing of antimicrobial therapy, hydrocortisone supplementation in stress doses, and an evaluation for drotrecogin alfa infusion. Antimicrobial therapy was judged to be either adequate or inadequate on the basis of the in vitro susceptibility of an isolated organism. Patients were considered to have prior antibiotic therapy if they had received an antimicrobial agent for at least 2 days within 30 days preceding onset of Pseudomonas bacteremia. Recurrent P. aeruginosa bacteremia was defined as P. aeruginosa bacteremia occurring within 30 days after completion of 14 days of adequate antimicrobial therapy. Reinfection was defined as the isolation of a P. aeruginosa strain that was genetically distinct from the initial strain isolated from blood culture. Overall mortality and invasive ventilation-free days was calculated in the first 30 days after the first positive blood culture. Survival of patients with multiple episodes of bacteremia was assessed at day 30 from the onset of bacteremia irrespective of the results of subsequent blood cultures.
Statistical Analysis
All analyses of patients were performed by investigators without knowledge of in vitro susceptibility results. SPSS 15.0 (SPPS, Cary, NC) was used for all statistical comparisons. The  level for significance was set at , 0.05. Continuous variables were analyzed using a two-tailed Student's t test for normally distributed variables and the Mann-Whitney test for non-normally distributed variables. Means and standard deviations are presented for normal data and medians with interquartile ranges for non-normally distributed data.
Proportions were compared using the chisquare test with Yates correction or Fisher's exact test when necessary. The relationship between Pseudomonas bacteremia and the outcome variables was investigated by a Coxproportional hazard model. All biologically plausible variables with a p value of , .20 in the bivariable analysis were considered for inclusion in the final multivariable regression models. A multicollinearity test was performed using the variance inflation factor to assess the degree of correlation between independent variables. A Kaplan-Meier product-limit method was used to estimate by univariate analysis the risk of death by presence of virulence factors in those who received adequate therapy. The cumulative probability of death across treatment groups was compared by the log-rank test.
RESULTS
Study Population
During the study period, a total of 89 patients with P. aeruginosa bacteremia were identified. Four patients were excluded from analysis due to polymicrobial bloodstream infection, leaving 85 cases for analysis. Thirty-seven patients (44%) had a P. aeruginosa isolate with at least one of the type 3 secretory proteins detected, while 48 patients (56%) were infected with isolates that did not express any of the type 3 secretory proteins. Table 1 displays the clinical characteristics of the study population. There were no significant differences in age, gender, underlying comorbidities, or in primary sites of infection between patients with TTSS1 and TTSS-isolates. Similarly, vital signs and laboratory parameters of the TTSS1 and TTSS-groups were comparable at the time the blood cultures were obtained ( Table 2 ). The median time from admission to culture positive was 2.0 days in both groups (p 5 .89). Septic shock was identified in 43% of bacteremic patients with TTSS1 isolates compared to 23% of patients with TTSS-isolates (p 5 .12). Although the need for vasopressors were similar in both groups, patients with TTSS1 isolates required a higher dose of norepinephrine in the first 48 hrs of onset of septic shock than those with TTSS-isolates (p 5 .02). Vasopressin and hydrocortisone were also prescribed more often in the TTSS1 compared to the TTSS-group but the difference did not attain statistical significance (p 5 .08 and p 5 .09, respectively). Figure 1 displays the immunoblot analysis of the of the type 3 secretion phenotypes in representative samples of P. aeruginosa isolates. The ExoU/ExoT phenotype was the most prevalent among all TTSS1 isolates and was detected in 18 out of 37 isolates (49%), while the ExoT/ ExoS was found in eight (22%). Of the 37 isolates, nine (24%) expressed ExoT alone while two (5%) expressed ExoS with no other exotoxins. None of the isolates expressed ExoU alone. Isolates that excreted ExoU did not release ExoS and vice versa. No significant association was found between the suspected focus on infection and the ability to secrete exotoxins, although a higher frequency of ExoU/ExoT was noted in isolates derived from a suspected respiratory source (Table 3 ). Figure 2 depicts DNA genotyping of representative P. aeruginosa isolates by repetitive-element-based polymerase chain reaction assay. The corresponding RAPD profiles for the type 3 secretory phenotypes are shown in Table 4 . Overall, there were 67 different RAPD fingerprints, 53 of which contained only one strain. The other 14 RAPD fingerprints had either clonal (n 5 6) or closely related stains (n 5 8). Strain relatedness was not associated with any particular secretory phenotype or time of bacteremia onset. There was also no correlation between the presumed focus on bacteremia and RAPD grouping.
Characterization of Type 3 Secretory Protein Phenotype
Antimicrobial Therapy
Forty-eight patients had previous exposure to antimicrobial therapy. Of those, 65% with TTSS1 isolates and 50% with TTSS-isolates had at least 2 days of antibiotics in the preceding 30 days of P. aeruginosa bacteremia (p 5 .25). Vancomycin (39%) and ciprofloxacin (24%) were the most commonly prescribed antibiotics in the TTSS1 group, while ciprofloxacin (21%) and cephalosporin (19%) accounted for the majority of prior antimicrobial therapy in TTSS-patients. There were no discernable differences in the prescription pattern of antibiotics between the two groups.
The average time to first antibiotic dose from a reported positive blood culture was 4.3 6 1.2 hrs. Empirical monotherapy for Gram-negative organisms was prescribed for 17 (46%) and 28 (58%) of the TTSS1 and the TTSS-groups, respectively (p 5 .36). Piperacillin/tazobactam was the predominant agent used in both groups (n 5 49), followed by ciprofloxacin (n 5 19) and cefepime (n 5 13). Combination therapy consisted mainly of piperacillin/tazobactam plus ciprofloxacin (n 5 12), and imipenem plus gentamicin (n 5 6). Overall, 15 (18%) out of 85 patients received inadequate antimicrobial therapy. Two patients in the TTSS1 and four patients in the TTSS-received no initial Gram-negative antibiotics directed against P. aeruginosa bloodstream infection. The remaining nine were treated with antibiotics having recognized activity against P. aeruginosa but for which the bacteria were actually resistant by in vitro susceptibility testing. The antimicrobial resistance profile of P. aeruginosa isolates are shown in Table 5 . Fifty-seven percent of isolates with TTSS1 phenotypes were resistant to two or more antimicrobial agents compared to 15% of TTSS-phenotype (p , .001). A higher frequency of resistance in the TTSS1 isolates was observed to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%) compared to TTSS-isolates. Piperacillin/ tazobactam had the least antimicrobial resistance in both groups. ExoU secretory phenotype was present in 11 out of 22 (50%) of ciprofloxacin-resistant isolates and in nine out of 14 (64%) gentamicinresistant isolates. In comparison, ExoS was identified in five (23%) of ciprofloxacinresistant isolates and in one of 14 (7%) gentamicin-resistant isolates.
Hospital Course and Outcome
During the course of hospitalization, six patients had recurrent P. aeruginosa bacteremia ( Table 6 ). The average time between the primary and secondary bloodstream infection isolates was 31 6 10 days. All recurrent P. aeruginosa isolates were considered reinfection due to a genetically distinct profile from the initial bacteremic isolates. There was no correlation between recurrence of bacteremia and secretory phenotypes.
The overall 30-day crude mortality was 32%. The 30-day and in-hospital mortality rates among patients with P. aeruginosa isolates that expressed TTSS1 protein were 46% and 57%, respectively, compared with 21% and 25% among patients whose P. aeruginosa did not express any of the exotoxins (p 5 .03 and 0.006, respectively). The survival curve also shows significant differences in the first 30-day cumulative probability of death after bacteremia between secretors and nonsecretors (p 5 .02) ( Fig. 3 ). All TTSS1 patients who did not survive to 30 days exhibited ExoU and/or ExoT phenotypes while none of the TTSS1 patients who survived the first 30 days had a P. aeruginosa isolate with an ExoU phenotype. There was a trend toward higher ventilator-free days in the TTSS-group compared to the TTSS1 group (22.7 6 17.9 days vs. 17.3 6 13.6 days) but the difference did not reach statistical significance (p 5 .09). Further, inadequate antimicrobial therapy was associated with worse 30-day outcome than those who had appropriate therapy irrespective of the TTSS phenotype (23% vs. 4%, respectively; p 5 .03). Cox-regression analysis identified Acute Physiologic and Chronic Health Evaluation II, the presence of TTSS phenotypes, and inadequate antimicrobial therapy as independent risk factors for 30-day mortality (hazard ratio 2.6 [95% confidence interval 1.1-6.2], 2.9 [95% confidence interval 1.3-6.7], and 3.1 [95% confidence interval 1.2-7.5], respectively) ( Table 7) .
DISCUSSION
The results of our study demonstrated that: 1) the prevalence of TTSS1 phenotype in P. aeruginosa bacteremia is common, with ExoU/ExoT representing the predominant phenotype; 2) there is a high association between antimicrobial resistance and TTSS1 phenotypes; and 3) type 3 protein secretion is associated with increased 30-day mortality in P. aeruginosa bacteremia.
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Figure 2.
DNA genotyping of representative Pseudomonas aeruginosa isolates by repetitive-elementbased polymerase chain reaction assay. Samples with identical banding patterns were considered to be related and assigned a single randomly amplified polymorphic DNA type. Samples with patterns that differed by one band were considered possibly related. Samples that differed by two or more bands were considered unrelated.
population based on the excretion of ExoU, ExoT, and ExoS. We have not investigated the presence of PcrV, PopB, or PopD because previous reports documented a lack of cytotoxicity of these proteins per se when tested in vitro (21, 22) . The proportion of TTSS1 strains that exhibited ExoU (48%) was higher than that reported by Berthelot et al (21) (28%) but close to that observed by Wareham et al (23) (40%). In contrast, the secretion of ExoS (27%) was lower than the reported rate of 52% in the study by Barthelot et al (21) . This wide range of prevalence among bacteremic P. aeruginosa isolates with the type 3 secretory proteins may be difficult to elucidate in the absence of a surveillance database. However, the almost ubiquitous presence of exoU1 and exoS1 genes in P. aeruginosa bloodstream isolates (24) suggests that the system is modulated by environmental cues that trigger the expression of TTSS genes. Unfortunately, further advance in this field is limited by the fact that TTSS expression is induced ex vivo through manipulation of the external milieu and not assessed in vivo. The use of in vivo gene expression technologies (25) may hold promise in accurately determining the spatial and temporal control of these impressively complex regulatory cascades. Previous studies have linked multidrug resistance in P. aeruginosa to TTSS phenotypes in ocular, blood, urine, and wound isolates (26, 27) . Wong-Beringer et al (27) studied this association by concentrating on fluoroquinolone-resistant clinical isolates of P. aeruginosa. Compared with exoS 1 isolates, exoU 1 isolates were more likely to be fluoroquinolone-resistant 
Exo, exotoxin. Lowercase letter indicates isolate differs from profile type by one band (possibly related). and to exhibit both a gyrA mutation and the efflux pump-overexpressed phenotype. More importantly, almost all exoU1 strains secreted ExoU. Although we have not performed a genotypic analysis, our results are in agreement with these observations, which suggest a coselection of fluoroquinolone resistance and enhanced TTSS virulence in isolates harboring exoU1. We noted also a high frequency of resistance for gentamicin among isolates secreting ExoU but not for ExoS. This resistance appears to be drug specific rather than class specific since the susceptibility to amikacin was not altered by the presence of the TTSS phenotypes.
Other investigators have demonstrated that the source of bacteremia, inadequate antimicrobial therapy, and severity of illness at the time of bacteremia are associated with a poor prognosis in P. aeruginosa infection (7, (28) (29) (30) . Our study suggests that type 3 secretory phenotype should be added to the growing list of factors responsible for increased mortality from P. aeruginosa bloodstream infection. The presence of a functional TTSS has already been linked to bacterial persistence in the lungs, higher relapse rates, and increased mortality in patients with acute respiratory infections (13, 16, 31) . Furthermore, secretion of type 3 proteins was associated with increased mortality in patients with a high bacterial burden in respiratory secretions but who failed to meet clinical criteria for the diagnosis of ventilator-associated pneumonia (14) . This is further substantiated in our study by the fact that, despite adequate antimicrobial therapy for both TTSS1 and TTSS-groups initially, patients with TTSS1 phenotype had a worse prognosis, most notably during the first few days. The same observation was reported in a retrospective analysis of 115 P. aeruginosa bloodstream infections (7) . The adequacy of the initial therapy did not influence survival up to receipt of the antibiogram. However, after censoring those patients that died during the first days, the risk of death for inadequate empirical treatment was significantly higher from the date of receipt of the antibiogram to day 30. Chamot et al (7) did not examine the phenotype of these isolates, but altogether these results suggest that a subpopulation of patients will die of P. aeruginosa bloodstream infection independently of their treatment. However, adequacy of empirical antimicrobial treatment influences the outcome of those patients that survive the first days following P. aeruginosa bloodstream infection.
There are several limitations to the present study that should be noted. First, we acknowledge the limitation of the retrospective design of the study, which might introduce bias that we are unable to adjust for using the collected indices. Despite the presence of protocol-driven intensive care unit management, changes in disease patterns and treatment strategies over the study period may have generated a time bias in our analysis, favoring late participants. It is increasingly recognized that outcomes also depend on a variety of clinical and nonclinical factors that are not measured and therefore cannot be adjusted for in the available models. Second, the P. aeruginosa blood culture data were collected from a single site; institutional differences in prescribing patterns, antibiotic formularies, and patient populations may affect the applicability of these results to other institutions. Third, we cannot exclude the possibility that a number of strains classified as TTSS-phenotype may exhibit type 3 secretory phenotypes based on the release of PcrV. These strains are, however, less virulent in vitro than those responsible for excretion of ExoU, ExoS, or ExoT (21) . Fourth, we have not assessed the expression of other virulence factors that may be coexpressed with the TTSS phenotype.
In conclusion, expression of the type 3 phenotype confers an increased virulence in P. aeruginosa bacteremia. The association between the ExoU phenotype and fluoroquinolone resistance needs to entail a prescription pattern that provides adequate coverage for suspected P. aeruginosa bacteremia in accordance with the local susceptibility profile. Interference with TTSS function by chemical or biological inhibition and vaccination has great potential to reduce the morbidity and mortality associated with infection with these pathogens. 
